← Compound index
COMPOUND RECORD / BONOTHYRK

BonothyrkБонотирк

A peptide mixture made from calf or pig parathyroid glands, studied in an institute report on bone mineral loss.

Source linked

What the studies found

Comparison in people · 2011

Bonothyrk: institute clinical report (commercially hosted translation)

Reported category of 15–20% bone mineral density loss
At three months, 94.7% in the Bonothyrk group and 90.5% in controls, as printed. The table gives a shared baseline of 90.5%.
Reported category of 20–25% bone mineral density loss
At three months, 5.3% with Bonothyrk and 14.4% in controls, as printed.

The 33-person report gives bone mineral density loss categories three months after treatment. The printed category percentages conflict with the stated group sizes.

Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology

Study notes · methods, sources and limitations

Participants or model 33 women aged 47–56: 20 preparation, 13 controls

Design 33 women aged 47–56 with climacteric symptoms and reduced bone mineral density. Twenty took two 10 mg capsules twice daily (40 mg/day) for 30 days. Thirteen took no intervention aimed at raising bone density. Densitometry was performed before treatment and three months after the course.

Important limitations

  • The signed original has not been authenticated. Allocation and masking are not described. The entry criterion and reported baseline categories are inconsistent. The control percentages do not sum to 100%. The report provides no fracture outcomes or interpretable between-group change in bone mineral density.
  • The table percentages cannot be reconciled with the stated group sizes and control percentages sum to 104.9%. The category figures do not provide a reliable between-group effect on bone density.

Institute-attributed report, 2011; commercially hosted brochure pp. 9–10 · Institute report — commercial reproduction

Original source or citation ↗

Study results and tables ↗
01 / OVERVIEW

About Bonothyrk

Identity / background source ↗

Research background

Bonothyrk is a calf parathyroid peptide preparation. A Medical Center report assessed bone mineral density in 33 women.

Compound class
Archival preparation lead
Research collection
Peptide bioregulation · editorial grouping
Institutions in linked studies
Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
Source review
Review dates and the material assessed are listed with each publication below.
02 / HOW TO READ THE RESEARCH

Understanding the evidence

Human research

33 women aged 47–56: 20 preparation, 13 controls

Study methods

Small adjunctive comparison; signed original, allocation and reporting require verification

Independent replication

New citations are not automatically independent replication; shared programs and translated reports require cohort checks

Source access

New indexed primary abstracts and/or report reproductions linked; review depth shown per source

Safety evidence

Reported tolerability is not proof of safety; uncommon harms and long-term outcomes remain unresolved

Open a topic for the evidence assessment.

More findings, background and history

What remains unclear

The original report and protocol would clarify group sizes, background treatment and translation. Independent replication and equivalence to current products remain uncertain.

Human reports are linked; their presence does not establish effectiveness. Several publications can describe the same participants.

Browse original study records ↗

Explore the expanded peptide research collection and unresolved source trails ↗

View this preparation in the Khavinson evidence map ↗

03 / SOURCE RECORDS

Findings by study

Tissue-preparation reports: comparisons, source limits and remaining gaps ↗

Explore related research ↗

Comparison in people · 2011

Bonothyrk: institute clinical report (commercially hosted translation)

The 33-person report gives bone mineral density loss categories three months after treatment. The printed category percentages conflict with the stated group sizes.

Reported category of 15–20% bone mineral density loss · At three months, 94.7% in the Bonothyrk group and 90.5% in controls, as printed. The table gives a shared baseline of 90.5%.

Study notes and original source
2011Human comparative studyFull text available

Bonothyrk: institute clinical report (commercially hosted translation)

Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology

Oral calf parathyroid tissue polypeptide complex · Institute report — commercial reproduction

Format: PDF · Reviewed: Report reproduction reviewed

St. Petersburg Institute of Bioregulation and Gerontology Medical Center (report attribution) · Institute-attributed report, 2011; commercially hosted brochure pp. 9–10

The 33-person report gives bone mineral density loss categories three months after treatment. The printed category percentages conflict with the stated group sizes.

Results and tables

Reported findings and study design

33 women aged 47–56 with climacteric symptoms and reduced bone mineral density. Twenty took two 10 mg capsules twice daily (40 mg/day) for 30 days. Thirteen took no intervention aimed at raising bone density. Densitometry was performed before treatment and three months after the course.

Population or model 33 women aged 47–56: 20 preparation, 13 controls

Results · Russian Medical Center report reproduction, methods and densitometry table
MeasureResultComparison, timing and statistics
Reported category of 15–20% bone mineral density lossAt three months, 94.7% in the Bonothyrk group and 90.5% in controls, as printed. The table gives a shared baseline of 90.5%.
Reported category of 20–25% bone mineral density lossAt three months, 5.3% with Bonothyrk and 14.4% in controls, as printed.

The table percentages cannot be reconciled with the stated group sizes and control percentages sum to 104.9%. The category figures do not provide a reliable between-group effect on bone density.

Source for these results ↗ · Reviewed 2026-11-16

Population / setting
33 women aged 47–56: 20 preparation, 13 controls
Source reviewed
Russian Medical Center report reproduction, methods and densitometry table.
Study limitations
  • The signed original has not been authenticated. Allocation and masking are not described. The entry criterion and reported baseline categories are inconsistent. The control percentages do not sum to 100%.
  • The report provides no fracture outcomes or interpretable between-group change in bone mineral density.

Reviewed 2026-11-16.

Read the source ↗

Follow shared publications or research classes. These links do not establish equivalent effects between compounds.

Research collection curated by @PepMariner · editorial standards. Send a source correction ↗

Browse bibliography & PDFs ↗